ImmunoPrecise Antibodies Ltd. Achieves Record Fiscal 2025 Revenue of $24.5M; Reports Improved Fourth Quarter Adjusted EBITDA of ($0.3)M

Reuters
Jul 29
ImmunoPrecise Antibodies Ltd. Achieves Record Fiscal 2025 Revenue of $24.5M; Reports Improved Fourth Quarter Adjusted EBITDA of ($0.3)M

ImmunoPrecise Antibodies Ltd. has announced its financial results for the fiscal year ending April 30, 2025. The company achieved a record-breaking revenue of $24.5 million, marking a significant achievement for the year. In the fourth quarter, the company reported its highest-ever revenue of $7.0 million. The fourth quarter also saw a record Adjusted EBITDA of ($0.3) million, indicating improved operating efficiency. The company achieved a gross margin of 64% in the fourth quarter, the strongest margin performance since the third quarter of the fiscal year 2021. Additionally, the BioStrand segment experienced remarkable growth of over 180% in fiscal year 2025, with gross margins approaching 90%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-099392), on July 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10